Loading…
Loading…
Alkermes (NASDAQ: ALKS - Get Free Report) and C4 Therapeutics (NASDAQ: CCCC - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, analyst recommendations and institutional ownership. Insider and Institutional Ownership 95.2% of Alkermes shares are
The executive sold 7,576 shares. The transaction resulted in a 7% reduction in the insider's direct equity holdings.
Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock?
Shares of Alkermes plc (NASDAQ: ALKS - Get Free Report) passed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $40.30 and traded as high as $49.35. Alkermes shares last traded at $49.16, with a volume of 660,776 shares. Wall Street Analysts Forecast Growth Several brokerages have
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the publication of data from the Vibrance‑1 phase 2 study of alixorexton in adults with narcolepsy type 1 (NT1) in The Lancet Neurology. Alixorexton is a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment of NT1, narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH). Based on the positive results demonstrated by alixorexton in the phase 2 Vibrance Studies in NT1 and NT2,.
Bank of America Corp DE decreased its stake in shares of Alkermes plc (NASDAQ: ALKS) by 9.2% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,210,851 shares of the company's stock after selling 122,254 shares during the quarter. Bank
Alkermes gains 26.5% in three months as strong proprietary product sales and pipeline progress fuel momentum into the rest of 2026.
Glenmede Trust Co. NA trimmed its position in shares of Alkermes plc (NASDAQ: ALKS) by 8.4% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 378,090 shares of the company's stock after selling 34,830 shares during the period. Glenmede Trust Co. NA owned about